课程概览
ICH Q12 provides a harmonised framework for management of post approval CMC changes more predictably and efficiently across the commercial lifecycle, using risk and science-based approaches and an effective Pharmaceutical Quality System (PQS).
The guideline introduces a set of practical tools and enablers, including risk-based categorisation of changes, Established Conditions (ECs), Post Approval Change Management Protocols (PACMPs), and the Product Lifecycle Management (PLCM) document, and explains how these connect to regulatory assessment and inspection expectations.
This course translates Q12 into real-world execution for the delegates and explains to them how to define ECs without ‘over locking’ the dossier, how to set reporting categories based on risk and knowledge, how to design PACMPs that regulators can approve, and how to keep lifecycle documentation inspection ready while enabling continual improvement.
This course is part of our
GxP training
(Good x Practice) course collection, which features a variety of topic areas to ensure you comply with the most recent quality guidelines.
Benefits of attending
Delegates will be able to:
Apply
ICH Q12 lifecycle tools to accelerate post-approval CMC change implementation while maintaining compliance and product quality
Define
and justify Established Conditions (ECs) to enable regulatory flexibility without over-locking the dossier
PACMPs with clear scope, studies, and acceptance criteria to improve predictability and reduce regulatory rework
Use
science- and risk-based approaches to categorise CMC changes and align reporting pathways across global regions (EU vs FDA)
Build
and govern the PLCM document as a living lifecycle tool linked to internal change control, ECs, and PACMP strategy
Integrate
ICH Q12 into the PQS (ICH Q10) using knowledge management, QRM, and change control to strengthen inspection readiness
Apply
Q12 through practical case studies and workshops covering site transfers, process optimisation, analytical changes, and frequent post-approval updates
Understand
Q12 implementation across FDA, EMA, MHRA, PMDA, Health Canada, and WHO, including legal and procedural differences by region
Strengthen
regulatory decision-making by recognising how assessors and inspectors interpret lifecycle data and apply 'flexibilities' in practice.
Who should attend
Regulatory affairs and submission authors
Quality assurance and pharmaceutical quality system owners
Change control leads and QRM specialists
MS&T, tech transfer, process development teams
Analytical development, quality control, method lifecycle owners
Supply chain, external manufacturing management specialist
Quality agreements owners
Program lifecycle management leads for marketed products
Day 1
课程大纲
Day 2
Why ICH Q12 matters: mindset for marketed products
Q12 relationship to ICH Q8, Q9, Q10, Q11
Regional adoption overview: FDA, EMA, PMDA, MHRA, Health Canada, WHO influence
Regional legal framework constraints (e.g., EU Variations model alignment)
Case study discussion: delayed global change implementation
ICH Q12 overview and key concepts
Scope of Q12 (DS vs DP;
small molecules;
biologics;
combinations)
Regulatory tools and enablers: ECs, PACMPs, PLCM
Categorisation of post-approval CMC changes
Dossier vs PQS responsibilities
Drug - device combination products: where ICHQ12 applies and where device regulation take over
Risk-based categorisation of post-approval CMC changes
Risk-based change categorisation principles
Role of product/process knowledge (development, validation, prior knowledge)
Group exercise: multi-region change classification scenarios
Apply Q9(R1) formality and subjectivity principles to change categorization decision
Established conditions (ECs): defining the flexible regulatory controls
Writing EC statements in CTD Module 3 (key sections)
Linking ECs to reporting categories
Lifecycle management of ECs (variations/supplements/PACMP routes)
Workshop: identifying ECs and drafting EC statements (mock dossier)
ECs in manufacturing: process performance and lifecycle controls
PAT and real-time monitoring as lifecycle enablers
Maintaining overall control strategy with fewer ECs
Lifecycle control of process EC changes (PLCM updates, PACMP alignment)
Case study: manufacturing change strategy using Q12 tools
Biologics manufacturing ECs - Annex IB and the role of Q5E comparability
Continuous manufacturing under ICHQ13 - interaction of EC concept with CM control strategies
ECs for analytical procedures
Analytical performance
Development knowledge impact on EC
Analytical change strategy
The Q14 interface - minimal vs enhanced approach to analytical procedures development in EC footprint
Post-approval change management protocols (PACMPs) - designing effective protocols
PACMP maturity
Acceptance criteria
Selection of PACMP
Workshop: design a PACMP package
Design PACMP for biologic products - role of ICHQ5E comparability data
PACMP: execution, reporting, and common pitfalls and knowledge management
PACMP execution planning and internal readiness
Repeatable PACMPs
Multi use/repeatable PACMPs
Case study: PLCM document review and improvement
Product lifecycle management (PCLM) document
PLCM content strategy
Lifecycle governance
Regional trends
Managing frequent changes and ‘immediate notification’ scenarios
Structured approaches to recurring change
Designing internal playbooks: data packages, decision trees, and success criteria
Inspection readiness for high change volumes
Supply chain strategy and regulatory communication
Knowledge management across complex supply chains
PQS–RA interface roles and governance model
CMO management and quality agreement considerations
Case examples: site transfer/CMO change management
Stability data and post approval changes
Stability expectations for post-approval changes
Predictive stability tools and modelling concepts
Commitments vs prior data (regional differences)
Biologics specific stability considerations